Divi's Labs In Focus: Citi Reaffirms 'Buy' With Rs 11,700 Target On Oral Wegovy Upside

Citi said Divi's has an integrated and cost-efficient peptide manufacturing platform, which could provide an advantage as demand for peptide-based therapies expands.
More news in Trending
Atlantic 'Cold Blob': Why Cooling Spot In Ocean Is Worrying Scientists World
41-Year-Old UFC Veteran Retires Following Tough Knockout Loss At UFC 332
Conor McGregor's UFC Future Questioned As Joe Rogan's Latest Comments
Redditor Lists 5 'Worst' Financial Mistakes; Urges Other To Learn From Them
Taking Career Break? Your EPF May Keep Earning Interest But There's A Tax Catch